Omeros Corp (OMER)

10.10
NASDAQ : Health Care
Prev Close 10.05
Day Low/High 9.89 / 10.56
52 Wk Low/High 7.20 / 16.80
Avg Volume 734.80K
Exchange NASDAQ
Shares Outstanding 42.92M
Market Cap 431.31M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of OMER January 2017 Options Trading

First Week of OMER January 2017 Options Trading

Investors in Omeros Corp saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

Omeros' Proprietary Orphan GPCR Program Delivers New Target And Approach In Cancer Immunotherapy

Omeros' Proprietary Orphan GPCR Program Delivers New Target And Approach In Cancer Immunotherapy

Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR) narrowly expressed in immune cells and linked to cancers, substantially and...

International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury

International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury

Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded €1.

Omeros Announces Successful Outcome Of OMIDRIA® Pediatric Cataract Trial

Omeros Announces Successful Outcome Of OMIDRIA® Pediatric Cataract Trial

Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA ® (phenylephrine and ketorolac injection) 1% / 0.

Single Dose Of Omeros' Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade Of The Alternative Pathway

Single Dose Of Omeros' Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade Of The Alternative Pathway

Omeros Corporation (NASDAQ: OMER) today announced pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates.

Omeros Corporation Reports Third Quarter 2016 Financial Results

Omeros Corporation Reports Third Quarter 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce Third Quarter 2016 Financial Results On November 9, 2016

Omeros Corporation To Announce Third Quarter 2016 Financial Results On November 9, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Announces Completion Of Initial Funding Under $125 Million Credit Facility

Omeros Announces Completion Of Initial Funding Under $125 Million Credit Facility

Omeros Corporation (NASDAQ: OMER) today announced that it has completed the initial funding under its senior secured credit facility with affiliates of CRG LP, a healthcare-focused investment firm, consisting of an $80...

Omeros Files Orphan Drug Application For OMS721 In Immunoglobulin A Nephropathy

Omeros Files Orphan Drug Application For OMS721 In Immunoglobulin A Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced that it has filed an application for orphan drug designation with the U.

Omeros Announces Positive Data From Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist In Heroin Users Treated With Buprenorphine/Naloxone

Omeros Announces Positive Data From Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist In Heroin Users Treated With Buprenorphine/Naloxone

Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in heroin-dependent subjects.

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

Omeros Requests Fast Track Designation For OMS721 For The Treatment Of IgA Nephropathy

Omeros Requests Fast Track Designation For OMS721 For The Treatment Of IgA Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced that it has requested fast track designation from the U.

2 Mistreated Small-Caps to Buy on Pullbacks

2 Mistreated Small-Caps to Buy on Pullbacks

Biotech Omeros and builder LGI Homes both seem substantially undervalued given their prospects.

Omeros Announces $125 Million New Credit Facility

Omeros Announces $125 Million New Credit Facility

Omeros Corporation (NASDAQ: OMER) today announced that it has entered into a senior credit facility with CRG LP, a healthcare-focused investment firm, to retire the company's existing credit facility, minimizing restricted...

First Week of December 16th Options Trading For Omeros (OMER)

First Week of December 16th Options Trading For Omeros (OMER)

Investors in Omeros Corp saw new options become available this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new December 16th contracts and identified one put and one call contract of particular interest.

Omeros Announces Positive Data From OMS721 Phase 2 Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Announces Positive Data From OMS721 Phase 2 Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ: OMER) today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) from the company's Phase 2 clinical trial of...

Omeros Announces Positive Data From Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist In Cocaine Abuse

Omeros Announces Positive Data From Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist In Cocaine Abuse

Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in patients with cocaine use...

Omeros Announces Positive Data From OMS721 Phase 2 Clinical Trial In Renal Diseases

Omeros Announces Positive Data From OMS721 Phase 2 Clinical Trial In Renal Diseases

Omeros Corporation (NASDAQ: OMER) today announced positive data from the company's Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, none of which currently have an approved treatment and all of which...

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Shares of Omeros fell almost 10% after analysts' downgraded the biotech.

Oversold Conditions For Omeros (OMER)

Oversold Conditions For Omeros (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase Omeros Corp At $8, Earn 18.2% Annualized Using Options

Commit To Purchase Omeros Corp At $8, Earn 18.2% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but cautious about paying the going market price of $10.20/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $8 strike, which has a bid at the time of this writing of 90 cents.

Omeros' MASP-2 Antibody Preserves Brain Tissue And Function In Stroke Models

Omeros' MASP-2 Antibody Preserves Brain Tissue And Function In Stroke Models

Omeros Corporation (NASDAQ: OMER) today announced results from its OMS721 complement program.

Omeros To Present At The 2016 Wedbush PacGrow Healthcare Conference

Omeros To Present At The 2016 Wedbush PacGrow Healthcare Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy In Paroxysmal Nocturnal Hemoglobinuria Model

Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy In Paroxysmal Nocturnal Hemoglobinuria Model

Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program.

Omeros Corporation Reports Second Quarter 2016 Financial Results

Omeros Corporation Reports Second Quarter 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce Second Quarter 2016 Financial Results On August 9, 2016

Omeros Corporation To Announce Second Quarter 2016 Financial Results On August 9, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...